NewAmsterdam Pharma Co NV NAMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $19.97
- Day Range
- $19.48–20.62
- 52-Week Range
- $17.90–42.21
- Bid/Ask
- $20.21 / $23.00
- Shares Outstanding
- 119.93M
- Market Cap
- $2.42B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 94.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 100
Valuation
Metric | NAMS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.83 |
Price/Sales | 94.97 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NAMS |
|---|---|
Quick Ratio | 11.46 |
Current Ratio | 11.76 |
Interest Coverage | — |
Quick Ratio
NAMS
Profitability
Metric | NAMS |
|---|---|
Return on Assets (Normalized) | −22.16% |
Return on Equity (Normalized) | −24.43% |
Return on Invested Capital (Normalized) | −26.99% |
Return on Assets
NAMS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|sQG!@> | LOCK|RB@Z | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>m&?fv? | LOCK|JCBD | $99B | |||
| Moderna Inc MRNA | LOCK|?qMK&W | LOCK|j$ | $90B | |||
| argenx SE ADR ARGX | LOCK|%ZZ?>&< | LOCK|wL | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Jlyf>!s | LOCK|&m | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|JQcQ@Dk | LOCK|N!Zd% | $31B | |||
| Incyte Corp INCY | LOCK|v#$Z$^ | LOCK|%< | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|rK$!?FK | LOCK|@!VN! | $22B | |||
| BioNTech SE ADR BNTX | LOCK|>pn@$< | LOCK|bxR | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<^fSY@P | LOCK|??& | $16B |
United States